These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 36302657

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Intraindividual Comparison of 99mTc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand 99mTc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer.
    Rathke H, Afshar-Oromieh A, Giesel FL, Kremer C, Flechsig P, Haufe S, Mier W, Holland-Letz T, De Bucourt M, Armor T, Babich JW, Haberkorn U, Kratochwil C.
    J Nucl Med; 2018 Sep; 59(9):1373-1379. PubMed ID: 29371410
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. An Analysis of the Diagnostic Performance of Tc-99m PSMA SSPECT/CT in Biochemically Recurrent Prostate Cancer Compared with Ga-68 PSMA PET/CT: A Single-center, Prospective Study.
    Ora M, Saini VK, Dixit M, Singh UP, Gambhir S.
    Indian J Nucl Med; 2024 Sep; 39(3):170-176. PubMed ID: 39291065
    [Abstract] [Full Text] [Related]

  • 25. Heterogeneity of [68Ga]Ga-PSMA-11 PET/CT in metastatic castration-resistant prostate cancer: genomic characteristics and association with abiraterone response.
    Pan J, Zhao J, Ni X, Zhu B, Hu X, Wang Q, Wei Y, Zhang T, Gan H, Wang B, Wu J, Song S, Liu C, Ye D, Zhu Y.
    Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1822-1832. PubMed ID: 36719427
    [Abstract] [Full Text] [Related]

  • 26. A prospective intra-individual comparison of [68Ga]Ga-PSMA-11 PET/CT, [68Ga]Ga-NODAGAZOL PET/CT, and [99mTc]Tc-MDP bone scintigraphy for radionuclide imaging of prostate cancer skeletal metastases.
    Lawal IO, Mokoala KMG, Mahapane J, Kleyhans J, Meckel M, Vorster M, Ebenhan T, Rösch F, Sathekge MM.
    Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):134-142. PubMed ID: 32424485
    [Abstract] [Full Text] [Related]

  • 27. Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy.
    Rosar F, Wenner F, Khreish F, Dewes S, Wagenpfeil G, Hoffmann MA, Schreckenberger M, Bartholomä M, Ezziddin S.
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1584-1594. PubMed ID: 34725725
    [Abstract] [Full Text] [Related]

  • 28. Tc-99m PSMA and Lu-177 PSMA Theranostic Pair in a Patient of Metastatic Castration Resistant Prostate Cancer.
    Sheikh N, Younis MN, Mumtaz M, Shahid A.
    J Pak Med Assoc; 2021 Nov; 71(11):2679-2682. PubMed ID: 34783763
    [Abstract] [Full Text] [Related]

  • 29. Head to head comparison performance of 99mTc-EDDA/HYNIC-iPSMA SPECT/CT and 68Ga-PSMA-11 PET/CT a prospective study in biochemical recurrence prostate cancer patients.
    García-Pérez FO, Davanzo J, López-Buenrostro S, Santos-Cuevas C, Ferro-Flores G, Jímenez-Ríos MA, Scavuzzo A, Santana-Ríos Z, Medina-Ornelas S.
    Am J Nucl Med Mol Imaging; 2018 Nov; 8(5):332-340. PubMed ID: 30510850
    [Abstract] [Full Text] [Related]

  • 30. 99m Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer.
    Schmidkonz C, Hollweg C, Beck M, Reinfelder J, Goetz TI, Sanders JC, Schmidt D, Prante O, Bäuerle T, Cavallaro A, Uder M, Wullich B, Goebell P, Kuwert T, Ritt P.
    Prostate; 2018 Jan; 78(1):54-63. PubMed ID: 29105797
    [Abstract] [Full Text] [Related]

  • 31. Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.
    Hofman MS, Emmett L, Sandhu S, Iravani A, Buteau JP, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, Francis RJ, Gedye C, Rutherford NK, Weickhardt A, Scott AM, Lee ST, Kwan EM, Azad AA, Ramdave S, Redfern AD, Macdonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang AY, Stockler MR, Williams SG, Martin AJ, Davis ID, TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group.
    Lancet Oncol; 2024 Jan; 25(1):99-107. PubMed ID: 38043558
    [Abstract] [Full Text] [Related]

  • 32. A Review on the Current State and Future Perspectives of [99mTc]Tc-Housed PSMA-i in Prostate Cancer.
    Brunello S, Salvarese N, Carpanese D, Gobbi C, Melendez-Alafort L, Bolzati C.
    Molecules; 2022 Apr 19; 27(9):. PubMed ID: 35565970
    [Abstract] [Full Text] [Related]

  • 33. 68 Ga-FAPI-46 PET/CT in a Metastatic Castration-Resistant Prostate Cancer Patient With Low PSMA Expression.
    Aryana K, Manafi-Farid R, Amini H, Divband G, Moghadam SZ.
    Clin Nucl Med; 2022 Nov 01; 47(11):972-973. PubMed ID: 35777753
    [Abstract] [Full Text] [Related]

  • 34. The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol.
    Pouliot F, Beauregard JM, Saad F, Trudel D, Richard PO, Turcotte É, Rousseau É, Probst S, Kassouf W, Anidjar M, Camirand Lemyre F, Bouvet GF, Neveu B, Tétu A, Guérin B.
    BJU Int; 2022 Sep 01; 130(3):314-322. PubMed ID: 34674367
    [Abstract] [Full Text] [Related]

  • 35. Response Assessment and Prediction of Progression-Free Survival by 68Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing 177Lu-PSMA-617 Radioligand Therapy.
    Khreish F, Wiessner M, Rosar F, Ghazal Z, Sabet A, Maus S, Linxweiler J, Bartholomä M, Ezziddin S.
    Biomolecules; 2021 Jul 26; 11(8):. PubMed ID: 34439768
    [Abstract] [Full Text] [Related]

  • 36. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging.
    Demirci E, Sahin OE, Ocak M, Akovali B, Nematyazar J, Kabasakal L.
    Nucl Med Commun; 2016 Nov 26; 37(11):1169-79. PubMed ID: 27333090
    [Abstract] [Full Text] [Related]

  • 37. Prostate-Specific Membrane Antigen Expression on PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study.
    Calderoni L, Maietti E, Farolfi A, Mei R, Louie KS, Groaning M, Fanti S.
    J Nucl Med; 2023 Jun 26; 64(6):910-917. PubMed ID: 36635087
    [Abstract] [Full Text] [Related]

  • 38. A single-center, multi-factor, retrospective study to improve the diagnostic accuracy of primary prostate cancer using [68Ga]Ga-PSMA-11 total-body PET/CT imaging.
    Lv J, Yu H, Yin H, Shi Y, Shi H.
    Eur J Nucl Med Mol Imaging; 2024 Feb 26; 51(3):919-927. PubMed ID: 37940684
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. 68Ga-PSMA PET/CT for Response Evaluation of 223Ra Treatment in Metastatic Prostate Cancer.
    de Jong AC, Segbers M, Ling SW, Graven LH, Mehra N, Hamberg P, Brabander T, de Wit R, van der Veldt AAM.
    J Nucl Med; 2023 Oct 26; 64(10):1556-1562. PubMed ID: 37536738
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.